Shamburg News · 8-K filed Nov 12, 2026, 7:07 AM EST

Parabilis Medicines Reports Third Quarter 2026 Financial Results and Business Updates

PBLS · Parabilis Medicines, Inc.

  • Earnings
  • Materiality: high

Parabilis Medicines, Inc. reported financial results for the quarter ended September 30, 2026, in a press release furnished as Exhibit 99.1. Revenue was $2.1 million, research and development expenses were $45.6 million, and general and administrative expenses were $11.3 million, producing a net loss of $44.5 million, or $0.36 per basic and diluted share. Cash, cash equivalents and marketable securities were $1.1 billion as of September 30, 2026, which the company expects to fund operations into 2030.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-456892.

Written from the filing by Shamburg Markets. Figures are as reported by the company.